Treatment of anti-CTLA4 in combination with cisplatin and anti-PD-1 enhanced antitumor immunity in TNBC, involved with activation of tumor-infiltrating cytotoxic CD8 and CD4 T cells [44]. This evidence concerns the gene CD4 and neoplasm.